IMUX raises €72.0M Growth round
5 January 2024· Mannheim, Germany· manufacturing, energy, robotics, b2b, software_hardware
The first tranche of $80 million will fund the ongoing clinical development of lead product candidates vidofludimus calcium (IMU-838), IMU-856, and IMU-381.
Investors
LeadBVF Partners L.P.
Also participating
RTW InvestmentsAvidity PartnersJanus Henderson InvestorsAdage Capital Partners LPSoleus Capital
About IMUX
Stage
Growth
Headquarters
Mannheim, Germany
Founded
2020
Team Size
6–20
Sectors
manufacturingenergyroboticsb2bsoftware_hardware
Source: https://www.imux.com/immunic-inc-announces-private-placement-of-up-to-240-million/